Home » Stocks » Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. (ARNA)

Stock Price: $63.27 USD -1.36 (-2.10%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 3.65B
Revenue (ttm) 4.61M
Net Income (ttm) -346.31M
Shares Out 57.65M
EPS (ttm) -6.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $63.27
Previous Close $64.63
Change ($) -1.36
Change (%) -2.10%
Day's Open 64.75
Day's Range 62.70 - 66.22
Day's Volume 428,934
52-Week Range 32.95 - 69.75

More Stats

Market Cap 3.65B
Enterprise Value 2.52B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 57.65M
Float 57.56M
EPS (basic) -6.86
EPS (diluted) -6.82
FCF / Share -5.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.40M
Short Ratio 6.69
Short % of Float 7.32%
Beta 1.41
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 790.49
PB Ratio 3.77
Revenue 4.61M
Operating Income -365.74M
Net Income -346.31M
Free Cash Flow -289.09M
Net Cash 1.12B
Net Cash / Share 19.48
Gross Margin 12,460.66%
Operating Margin -7,926.83%
Profit Margin -7,505.70%
FCF Margin -6,265.47%
ROA -17.42%
ROE -28.34%
ROIC -36.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 12
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(30.52% upside)
Current: $63.27
Target: 82.58
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth4387.65%-15.78%-76.85%587.89%-63.76%-54.58%195.04%116.9%-23.44%-
Gross Profit80617.9721.3492.1613.4029.2175.2123.924.629.20
Operating Income483-145-91.97-5.26-104-105-22.94-57.11-82.80-96.36
Net Income398-29.40-91.41-22.52-108-60.51-19.44-85.48-109-125
Shares Outstanding49.7847.0432.9924.3124.0721.9721.8119.6513.9210.96
Earnings Per Share7.69-0.63-2.77-0.93-4.49-2.80-0.90-4.50-8.00-11.40
Operating Cash Flow569-132-66.64-61.48-98.11-10172.80-44.05-78.26-52.32
Capital Expenditures-4.82-0.690.680.141.11-8.86-9.10-1.75-0.59-4.16
Free Cash Flow564-133-65.97-61.34-97.00-11063.70-45.79-78.84-56.48
Cash & Equivalents74044624790.7115616322215657.63151
Total Debt49.4352.7161.7565.2768.2570.7472.7974.4690.47125
Net Cash / Debt69039318525.4587.9492.4714981.63-32.8425.76
Book Value1,07160620739.9053.5447.3591.8698.6410.5680.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Arena Pharmaceuticals, Inc.
Country United States
Employees 320
CEO Amit Dilip Munshi

Stock Information

Ticker Symbol ARNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARNA
IPO Date July 28, 2000


Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.